KRAS and colorectal carcinoma: Our findings that α3β1 is pro-migratory/pro-invasive in CRC cells but dispensable for colonic dysplasia during early stages of KRAS-mutated CRC indicate stage-specific requirements for this integrin during CRC progression, and they raise important considerations regarding the exploitation of α3β1 as a potential therapeutic target for CRC treatment.